ECOR electroCore
- 6.2394
- +0.5394+9.46%
electroCore News
Truvaga Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion
Express News | ElectroCore Launches Truvaga Plus For General Wellness
ElectroCore Announces the Launch of Truvaga Plus for General Wellness
ROCKAWAY, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the launch of its direct-to-consumer mobile
Analysts Are Bullish on These Healthcare Stocks: Electrocore (ECOR), Viking Therapeutics (VKTX)
Express News | HC Wainwright & Co. Reiterates Buy on ElectroCore, Maintains $15 Price Target
Electrocore's Growth Trajectory: A Buy Rating With Promising Prospects
Earnings Call Summary | ElectroCore(ECOR.US) Q4 2023 Earnings Conference
The following is a summary of the ElectroCore, Inc. (ECOR) Q4 2023 Earnings Call Transcript:Financial Performance:ElectroCore reported a significant increase in annual revenue in 2023, growing by 87%
ElectroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates
ElectroCore Q4 2023 GAAP EPS $(0.61), Inline, Sales $5.191M Beat $4.967M Estimate
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.61) per share which met the analyst consensus estimate. The company reported quarterly sales of $5.191 million which beat the analyst consen
Earnings Flash (ECOR) ELECTROCORE Posts Q4 Revenue $5.2M, Vs. Street Est of $5M
04:06 PM EDT, 03/13/2024 (MT Newswires) -- Earnings Flash (ECOR) ELECTROCORE Posts Q4 Revenue $5.2M, vs. Street Est of $5M
ElectroCore 4Q Loss/Shr 61c >ECOR
ElectroCore 4Q Loss/Shr 61c >ECOR
Earnings Scheduled For March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. • Silence Therapeutics (NASDAQ:SLN) is expec
Notable Earnings After Wednesday's Close
A Preview Of ElectroCore's Earnings
electroCore (NASDAQ:ECOR) is set to give its latest quarterly earnings report on Wednesday, 2024-03-13. Here's what investors need to know before the announcement.Analysts estimate that electroCore wi
ElectroCore to Participate in Upcoming Investor Conferences
ROCKAWAY, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company's Chief Strategy
ElectroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024
ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the fourth
ElectroCore Expands Intellectual Property Portfolio With U.S. Patent No. 11,894,148 Entitled "Systems And Methods For Treating Patients With Diseases Associated With Viruses"
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems an
Express News | HC Wainwright & Co. Maintains Buy on ElectroCore, Raises Price Target to $15
ElectroCore Expands Intellectual Property Portfolio; Trademark Office Has Issued A Patent Related To Systems And Methods For Treating Post-traumatic Stress Disorder
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems an
ElectroCore Expands Intellectual Property Portfolio; The Two Patents Were Issued On December 26, 2023, And Relate To ElectroCore's Non-Invasive Vagus Nerve Stimulation Technology
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trade
Analysis
Price Target
No Data
